The MBA Intern will support global launch readiness for a rare disease therapy by developing scenario frameworks, decision trees, and governance plans based on Phase 3 data outcomes.

The intern will enhance biostatistics workflows through AI applications, automate quality reviews, and contribute to innovative dataset tools and report generation. Collaboration with biostatisticians is key.

This internship involves conducting literature reviews, analyzing data, and drafting abstracts and manuscripts related to rare diseases and Clinical Outcomes Assessments.